Key result
Adjunctive alpha-lipoic acid reduces inflammation and improves cardiac function in diabetic ischemic cardiomyopathy.
Why the study?
Alpha-lipoic acid has antioxidant and anti-inflammatory effects, but its effects on left ventricular dysfunction and myocardial fibrosis in ischemic cardiomyopathy remain unclear.
Does alpha-lipoic acid reduce inflammation and improve cardiac function in diabetic patients with ischemic cardiomyopathy?
RCT (n=67)
Double-blind
randomized
No
Does alpha-lipoic acid reduce inflammation and improve cardiac function in diabetic patients with ischemic cardiomyopathy?
p-value: p=<0.05
Alpha-lipoic acid added to standard therapy may reduce inflammation and improve cardiac function in diabetic patients with ischemic cardiomyopathy.
Supports adjunctive alpha-lipoic acid in diabetic ischemic cardiomyopathy; extends antioxidant evidence to this population.
BACKGROUND: Ischemic cardiomyopathy (ICM) is caused by oxidative stress, inflammation, and apoptosis. Alpha-lipoic acid (ALA) has antioxidant and anti-inflammatory effects. However, its effects on left ventricular dysfunction and myocardial fibrosis remain unclear. OBJECTIVE: This study aims to investigate the effects of ALA on cardiac inflammation, fibrosis, and myocardial function as an adjuvant therapy for ICM. METHODS: This double-blind, randomized, placebo-controlled, single-center trial enrolled 67 diabetic patients with ICM, who were randomized to receive either ALA 600 mg once daily or placebo for three months, in addition to ICM medications. Both groups were evaluated for tumor necrosis factor-alpha (TNF-α), C-reactive protein (CRP), tissue growth factor-β1 (TGF-β1), matrix metalloproteinase-2 (MMP-2), and some echocardiographic indices before and after treatment. RESULTS: < 0.05), respectively. CONCLUSION: Adjunctive ALA therapy considerably reduced inflammation and improved cardiac function in patients with ICM. Additionally, our findings suggest that ALA may influence profibrotic signaling.
No takes yet. Share an insight, caveat, or question.
Shama et al. (2025) conducted an RCT in Ischemic cardiomyopathy in type 2 diabetic patients (n=67). Alpha-lipoic acid (ALA) vs. Placebo was evaluated on Tumor necrosis factor-alpha (TNF-α), C-reactive protein (CRP), tissue growth factor-β1 (TGF-β1), matrix metalloproteinase-2 (MMP-2), and echocardiographic indices (p=<0.05). Adjunctive alpha-lipoic acid therapy considerably reduced inflammation and improved cardiac function in diabetic patients with ischemic cardiomyopathy (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: